Clinical Trials Browser

Completed × capivasertib × Clear all

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

NCT07088913 2026-03-03

A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Rosuvastatin in Healthy Participants

Phase 1 Completed

20 enrolled

Healthy Participants

NCT01226316 2025-06-29

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

Phase 1 Completed

285 enrolled

BreastGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT02423603 2025-03-10

PAKT

Phase 2 Completed

71 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT05008055 2024-12-20

CAPITAL

Phase 2 Completed

30 enrolled 15 charts

Lymphoid

Lymphoma, Follicular, Recurrence, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT02338622 2024-09-26

ComPAKT

Phase 1 Completed

60 enrolled

Advanced Cancer

NCT04958226 2024-01-25

A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid Tumours

Phase 1 Completed

21 enrolled

Other solid neoplasm

Solid Tumour

NCT02117167 2024-01-10

SAFIR02_Lung

Phase 2 Completed

999 enrolled

Thoracic

Non-small Cell Lung Cancer Metastatic

NCT03310541 2023-05-06

AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations

Phase 1 Completed

12 enrolled

BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT04742036 2022-08-19

Capivasertib China PK Study

Phase 1 Completed

16 enrolled

Other solid neoplasm

Advanced Solid Tumours

NCT04087174 2022-07-13

A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer

Phase 1 Completed

27 enrolled

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT04944771 2022-05-09

Study to Assess the Effect of Food and Acid Reducing Agents on the Absorption of Capivasertib in Healthy Participants

Phase 1 Completed

48 enrolled

Other hematologic neoplasm

Hematologic Neoplasms

NCT02121639 2022-05-05

ProCAID

Phase 1/2 Completed

160 enrolled

Genitourinary

Prostatic Neoplasms

NCT04712396 2021-04-09

A Study to Assess How Itraconazole Affects the Uptake and Elimination of Capivasertib in the Body

Phase 1 Completed

11 enrolled

BreastGenitourinary

Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer)

NCT02451956 2019-12-30

Study of AZD5363 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring PIK3CA Mutation and/or PIK3CA Amplification as a Second-line Chemotherapy

Phase 2 Completed

21 enrolled

Gastrointestinal

Advanced Gastric Cancer

NCT02077569 2017-05-04

STAKT

Phase 2 Completed

48 enrolled

Breast

Breast Neoplasms

NCT01895946 2016-05-25

OAK

Phase 1 Completed

33 enrolled 14 charts

Advanced Solid Malignancy,

NCT01353781 2016-04-26

Open Label Phase 1 Study in Japan for Patient With Advanced Solid Malignancies

Phase 1 Completed

39 enrolled

Other solid neoplasm

Advanced Solid Malignancy

Clinical Trials

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Rosuvastatin in Healthy Participants

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

PAKT

CAPITAL

ComPAKT

A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid Tumours

SAFIR02_Lung

AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations

Capivasertib China PK Study

A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer

Study to Assess the Effect of Food and Acid Reducing Agents on the Absorption of Capivasertib in Healthy Participants

ProCAID

A Study to Assess How Itraconazole Affects the Uptake and Elimination of Capivasertib in the Body

Study of AZD5363 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring PIK3CA Mutation and/or PIK3CA Amplification as a Second-line Chemotherapy

STAKT

OAK

Open Label Phase 1 Study in Japan for Patient With Advanced Solid Malignancies